Sign In

A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Representative Results
  • Discussion
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

In this paper we present a detailed protocol for non-invasive liquid biopsy technique, including blood collection, plasma and buffy coat separation, cfDNA and germline DNA extraction, quantification of cfDNA or germline DNA, and cfDNA fragment enrichment analysis.

Abstract

Identifying mutations in tumors of cancer patients is a very important step in disease management. These mutations serve as biomarkers for tumor diagnosis as well as for the treatment selection and its response in cancer patients. The current gold standard method for detecting tumor mutations involves a genetic test of tumor DNA by means of tumor biopsies. However, this invasive method is difficult to be performed repeatedly as a follow-up test of the tumor mutational repertoire. Liquid biopsy is a new and emerging technique for detecting tumor mutations as an easy-to-use and non-invasive biopsy approach.

Cancer cells multiply rapidly. In parallel, numerous cancer cells undergo apoptosis. Debris from these cells are released into a patient’s circulatory system, together with finely fragmented DNA pieces, called cell-free DNA (cfDNA) fragments, which carry tumor DNA mutations. Therefore, for identifying cfDNA based biomarkers using liquid biopsy technique, blood samples are collected from the cancer patients, followed by the separation of plasma and buffy coat. Next, plasma is processed for the isolation of cfDNA, and the respective buffy coat is processed for the isolation of a patient's genomic DNA. Both nucleic acid samples are then checked for their quantity and quality; and analyzed for mutations using next-generation sequencing (NGS) techniques.

In this manuscript, we present a detailed protocol for liquid biopsy, including blood collection, plasma, and buffy coat separation, cfDNA and germline DNA extraction, quantification of cfDNA or germline DNA, and cfDNA fragment enrichment analysis.

Introduction

Technological advances have led to the sequencing of hundreds of cancer genomes and transcriptomes1. This has contributed to understanding landscapes of molecular changes across different cancer types2. Further studies on these landscapes have helped characterize the sequential somatic alterations and gene-gene fusions3 that are involved in cancer or tumor progression, by serially disrupting apoptosis pathways4. Therefore, somatic mutations and gene-gene fusions can provide information about tumors by serving as biomarkers in individual patients for a particular tumor type<....

Protocol

Prior to blood collection, informed consent from subjects participating in the research is required and must be obtained. The research described in this manuscript was performed in accordance and compliance with the Rabin Medical Center, Israel ethic committee (ethic code: 0039-17-RMC) and the Faculty of Medicine Der Christian-Albrechts-Universität zu Kiel, Germany ethic committee (ethic code: D 405/14).

1. Blood sample collection and storage in cfDNA or cfRNA preservative tubes

    <.......

Representative Results

Plasma Separation
8.5-9 mL blood collected in cfDNA or cfRNA preservative tubes yields around ~4 mL plasma in volume. The volume of plasma separated from blood collected in EDTA tubes may vary depending on the temperature. Exposure of EDTA tubes containing blood at a temperature higher than 37 °C leads to decreased plasma volume yield44.

Fluorometer Assay Results
cfDNA concentration in 1 mL plasma of each of glioma pati.......

Discussion

The collection of a patient’s blood in a tube, shipment and storage are crucial initial steps in liquid biopsy. Improper handling can impair the quality of the plasma and, therefore, can interfere with the results of the liquid biopsy47. If a blood sample is collected in an EDTA blood tube, the plasma must be separated within two hours of blood collection to avoid lysis of WBCs and release of its genomic DNA into the plasma48. WBCs can also undergo apoptosis in an EDT.......

Acknowledgements

The authors would like to thank the members of the Laboratory of Cancer Genomics and Biocomputing of Complex Diseases for their keen observational inputs and their participation in multiple discussions at different stages of this project. The funding support includes Israel Cancer Association (ICA grant for M.F-M 2017-2019) and Kamin grant of Israel Innovation Authority (for M.F-M.).

....

Materials

NameCompanyCatalog NumberComments
2100 Bioanalyzer InstrumentAgilent Technologies, Inc.G2939BAThe 2100 Bioanalyzer system is an established automated electrophoresis tool for the sample quality control of biomolecules.
Adjustable Clip for Priming StationAgilent Technologies, Inc.5042-1398Used in combination with syringe to apply defined pressure for chip priming.
Agilent High Sensitivity DNA KitAgilent Technologies, Inc.5067-4626The High Sensitivity DNA assays are often used for sample quality control for next-generation sequencing libraries
cf-DNA/cf-RNA Preservative TubesNorgen Biotek Corp.63950Norgen's cf-DNA/cf-RNA Preservative Tubes are closed, evacuated plastic tubes for the collection and the preservation of cf-DNA, circulating tumor DNA, cf-RNA and circulating tumor cells in human whole blood samples during storage and shipping
Chip Priming StationAgilent Technologies, Inc.5065-4401Used to load gel matrix into a chip with a syringe provided with each assay kit— used for RNA, DNA, and protein assays. Includes priming station, stop watch, and 1 syringe clip
Electrode Cleaner KitAgilent Technologies, Inc.5065-9951Prevents cross-contamination. Removes bacterial or protein contaminants from electrodes.
Filters for Gel MatrixAgilent Technologies, Inc.185-5990Used for proper mixing of DNA dye concentrate and DNA gel matrix
IKA Basic Chip VortexIKA-Werke GmbH & Co. KGMS-3-S36Used for proper mixing of DNA ladder and DNA sample on Bioanalyzer assay chips
NucleoSpin Tissue kitMACHEREY-NAGEL740952.5With the NucleoSpin Tissue kit, genomic DNA can be prepared from tissue, cells
(e.g., bacteria), and many other sources.
QIAamp circulating nucleic acid kitQiagen55114The QIAamp Circulating Nucleic Acid Kit enables efficient purification of these circulating nucleic acids from human plasma or serum and other cell-free body fluids.
QIAvac 24 Plus vacuum manifoldQiagen19413The QIAvac 24 Plus vacuum manifold is designed for vacuum processing of QIAGEN columns in parallel.
QIAvac Connecting SystemQiagen19419In combination with the QIAvac Connecting System, the QIAvac 24 Plus vacuum manifold can be used as a flow-through system. The sample flow-through, containing possibly infectious material, is collected in a separate waste bottle.
Qubit 2.0 fluorometerInvitrogenQ32866The Qubit 2.0 Fluorometer is an easy-to-use, analytical instrument designed to work with the Qubit assays for DNA, RNA, and protein quantitation.
Qubit assay tubesThermo Fisher ScientificQ32856Qubit assay tubes are 500 µL thin-walled polypropylene tubes for use with the Qubit Fluorometer.
Qubit dsDNA HS Assay KitThermo Fisher ScientificQ32851The Qubit dsDNA HS (High Sensitivity) Assay Kit is designed specifically for use with the Qubit Fluorometer. The assay is highly selective for double-stranded DNA (dsDNA) over RNA and is designed to be accurate for initial sample concentrations from 10 pg/µL to 100 ng/µL.
Vacuum PumpQiagen84010used for vacuum processing of QIAGEN columns
Miscellaneous
50 ml centrifuge tubes
Crushed ice
Ethanol (96–100%)
Heating block or similar at 56 °C (capable of holding 2 ml collection tubes)
Isopropanol (100%)
Microcentrifuge
Phosphate-buffered saline (PBS)
Pipettes (adjustable)
Sterile pipette tips (pipette tips with aerosol barriers are recommended to help prevent cross-contamination)
Water bath or heating block capable of holding 50 mL centrifuge tubes at 60 °C

References

  1. Campbell, P. J., et al. Pan-cancer analysis of whole genomes. Nature. 578 (7793), 82-93 (2020).
  2. Liotta, L., Petricoin, E. Molecular profiling of human cancer. Nature Reviews Genetics. 1 (1), 48-56 (2000).
  3. Balamurali, D., et a....

Explore More Articles

Cell free DNALiquid BiopsyTumor MutationsTumor FusionsNon invasiveCancer Disease ProgressionPlasma SampleProteinase KLysis BufferBinding BufferSilica Membrane ColumnWash BufferEthanolElution BufferDNA Fragment Analysis

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2024 MyJoVE Corporation. All rights reserved